# Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/comparison-of-three-scoring-methods-using-the-fda-approved-22c3/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hua Guo,Qingqing Ding,Yun Gong,Michael Z. Gilcrease,Min Zhao,Jun Zhao,Dawen Sui,Yun Wu,Hui Chen,Hui Liu,Jinxia Zhang,Erika Resetkova,Stacy L. Moulder,Wei‐Lien Wang,Lei Huo |
| Citations | 71 |
| DOI | 10.1186/s13058-020-01303-9 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/s13058-020-01303-9 |
| OpenAlex ID | https://openalex.org/W3036479961 |
| PMID | 32576238 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Jinxia Zhang](https://scholariq.org/researchers/jinxia-zhang/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.